Kaan Kavaklı

3.0k total citations
94 papers, 1.5k citations indexed

About

Kaan Kavaklı is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Kaan Kavaklı has authored 94 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Hematology, 21 papers in Genetics and 15 papers in Surgery. Recurrent topics in Kaan Kavaklı's work include Hemophilia Treatment and Research (57 papers), Blood Coagulation and Thrombosis Mechanisms (26 papers) and Platelet Disorders and Treatments (16 papers). Kaan Kavaklı is often cited by papers focused on Hemophilia Treatment and Research (57 papers), Blood Coagulation and Thrombosis Mechanisms (26 papers) and Platelet Disorders and Treatments (16 papers). Kaan Kavaklı collaborates with scholars based in Türkiye, United States and Italy. Kaan Kavaklı's co-authors include Erik Berntorp, Johannes Oldenburg, Jan Astermark, Jerzy Windyga, Tadashi Matsushita, Steven R. Lentz, Víctor Jiménez‐Yuste, A. Pavlova, Jonas Carlson and Ann Kari Lefvert and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kaan Kavaklı

90 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaan Kavaklı Türkiye 22 1.2k 324 220 209 102 94 1.5k
NK Ramsay United States 18 1.3k 1.1× 417 1.3× 168 0.8× 266 1.3× 185 1.8× 37 1.7k
Chezi Ganzel Israel 17 627 0.5× 181 0.6× 291 1.3× 100 0.5× 71 0.7× 67 911
Nilgün Sayınalp Türkiye 16 511 0.4× 203 0.6× 142 0.6× 61 0.3× 100 1.0× 84 875
Diana S. Beardsley United States 17 877 0.7× 168 0.5× 106 0.5× 221 1.1× 148 1.5× 30 1.3k
Judith Behrens United Kingdom 10 752 0.6× 219 0.7× 468 2.1× 117 0.6× 129 1.3× 18 1.1k
Carolyn M. Bennett United States 18 782 0.6× 180 0.6× 65 0.3× 88 0.4× 96 0.9× 48 983
H. Heimpel Germany 15 706 0.6× 295 0.9× 113 0.5× 116 0.6× 75 0.7× 38 1.1k
G Broccia Italy 16 695 0.6× 243 0.8× 172 0.8× 93 0.4× 51 0.5× 39 931
Kathleen Jentsch‐Ullrich Germany 15 313 0.3× 243 0.8× 140 0.6× 141 0.7× 89 0.9× 46 882
Seung‐Ah Yahng South Korea 18 752 0.6× 181 0.6× 160 0.7× 65 0.3× 28 0.3× 88 1.0k

Countries citing papers authored by Kaan Kavaklı

Since Specialization
Citations

This map shows the geographic impact of Kaan Kavaklı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaan Kavaklı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaan Kavaklı more than expected).

Fields of papers citing papers by Kaan Kavaklı

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaan Kavaklı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaan Kavaklı. The network helps show where Kaan Kavaklı may publish in the future.

Co-authorship network of co-authors of Kaan Kavaklı

This figure shows the co-authorship network connecting the top 25 collaborators of Kaan Kavaklı. A scholar is included among the top collaborators of Kaan Kavaklı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaan Kavaklı. Kaan Kavaklı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Young, Guy, Kaan Kavaklı, Robert Klamroth, et al.. (2025). Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 145(25). 2966–2977. 7 indexed citations
2.
Vahabi, Arman, et al.. (2024). Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees. Haemophilia. 30(4). 1043–1049. 1 indexed citations
3.
Aydoğdu, Semih, et al.. (2024). Rifampicin-Induced Toxic Hepatitis in a Patient with Hemophilia After Chemical Synovectomy. Turkish Journal of Hematology. 41(1). 64–65.
4.
Kenet, Gili, Beatrice Nolan, Bülent Zülfikar, et al.. (2024). Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 143(22). 2256–2269. 16 indexed citations
5.
Leavitt, Andrew D., Kaan Kavaklı, Laurent Frenzel, et al.. (2024). Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial. Blood. 144(Supplement 1). 1053–1053. 2 indexed citations
6.
7.
Çoğulu, Özgür, et al.. (2023). A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis. Journal of Thrombosis and Haemostasis. 21(10). 2913–2916. 4 indexed citations
8.
Frenzel, Laurent, Kaan Kavaklı, Robert Klamroth, et al.. (2023). Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis. Blood. 142(Supplement 1). 2257–2257. 2 indexed citations
9.
Alzahrani, Hazzaa, Adam Cuker, Όλγα Κατσαρού, et al.. (2023). PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec. Research and Practice in Thrombosis and Haemostasis. 7. 101217–101217. 1 indexed citations
10.
11.
Gülen, Figen, et al.. (2020). Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa. Pediatric Allergy Immunology and Pulmonology. 33(3). 159–162. 1 indexed citations
12.
Mackensen, Sylvia von, Kaan Kavaklı, Anna Klukowska, et al.. (2019). The impact of psychosocial determinants on caregivers’ burden of children with haemophilia (results of the BBC study). Haemophilia. 25(3). 424–432. 16 indexed citations
13.
Shapiro, Amy D., Pantep Angchaisuksiri, Jan Astermark, et al.. (2019). Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 134(22). 1973–1982. 108 indexed citations
14.
Stasyshyn, Oleksandra, Margarita Timofeeva, Nicola Curry, et al.. (2018). Evaluation of the effect on endogenous factor VIII activity (FVIII: C) after recombinant von Willebrand factor (rVWF) administration during the elective surgery study in patients with severe von Willebrand disease (VWD). Haemophilia. 24. 107–108. 1 indexed citations
15.
Özçetin, Mustafa, et al.. (2011). Rate Of Abnormal Coagulation Test Results in Patients with Congenital Heart Disease. DergiPark (Istanbul University). 1(1). 6–10. 2 indexed citations
16.
Baran, Maşallah, et al.. (2010). Giant cell hepatitis and autoimmune hemolytic anemia after chickenpox. The Turkish Journal of Gastroenterology. 21(4). 448–451. 5 indexed citations
17.
Kavaklı, Kaan, Semih Aydoğdu, Yusuf Duman, et al.. (2008). Radioisotope synovectomy with rhenium186in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia. 14(3). 518–523. 25 indexed citations
18.
Astermark, Jan, Johannes Oldenburg, Jonas Carlson, et al.. (2006). Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 108(12). 3739–3745. 160 indexed citations
19.
Aydoğdu, Semih, Ahmet Memiş, Kaan Kavaklı, & Can Balkan. (2001). The pelvi‐femoral incomplete bone bridge in a patient with mild haemophilia. Haemophilia. 7(2). 224–226. 7 indexed citations
20.
Kavaklı, Kaan, Zafer Kurugöl, Damla Gökşen, & Güngör Nişli. (2000). SHOULD HEMOPHILIAC PATIENTS BE CIRCUMCISED?. Pediatric Hematology and Oncology. 17(2). 149–153. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by NK Ramsay Breakdown of academic impact, for papers by Chezi Ganzel Breakdown of academic impact, for papers by Nilgün Sayınalp Breakdown of academic impact, for papers by Diana S. Beardsley Breakdown of academic impact, for papers by Judith Behrens Breakdown of academic impact, for papers by Carolyn M. Bennett Breakdown of academic impact, for papers by H. Heimpel Breakdown of academic impact, for papers by G Broccia Breakdown of academic impact, for papers by Kathleen Jentsch‐Ullrich Breakdown of academic impact, for papers by Seung‐Ah Yahng
Rankless by CCL
2026